Amarin added that this unnamed PBM accounted for almost 25% of the U.S. Vascepa prescription volumes generated from this channel.However, the decision will not impact PBM's Medicare Part D ...

Shares of Amarin Corporation AMRN rose 7.1% on Wednesday after management announced positive updates on its intellectual property portfolio for its sole marketed drug, Vazkepa, in Europe.

Amarin has a twelve month low of $0.43 and a twelve month high of $1.37. The stock has a fifty day simple moving average of $0.51 and a 200 day simple moving average of $0.59. Get Amarin alerts ...

Amarin is on course to significantly increase the number of patients eligible for treatment with its purified fish oil drug Vascepa after an FDA advisory committee voted in favour of an expanded ...

DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Peter Fishman has been appointed as Chief Financial Officer for the ...

He will be responsible for leading Amarin’s global finance organization and will report directly to the Company’s Chief Executive Officer, Aaron Berg. Most recently, Mr. F Amarin (AMRN ...

Amarin said in a statement that this is the first drug in the class to be recommended by NICE for cardiovascular risk reduction. The final guidance is expected to be published on 20 July.

Amarin has a 52-week low of $0.43 and a 52-week high of $1.37. The stock has a market capitalization of $226.61 million, a P/E ratio of -6.13 and a beta of 1.82. Get Amarin alerts: Amarin (NASDAQ ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...